ZA200700030B - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
ZA200700030B
ZA200700030B ZA200700030A ZA200700030A ZA200700030B ZA 200700030 B ZA200700030 B ZA 200700030B ZA 200700030 A ZA200700030 A ZA 200700030A ZA 200700030 A ZA200700030 A ZA 200700030A ZA 200700030 B ZA200700030 B ZA 200700030B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
ZA200700030A
Other languages
English (en)
Inventor
Murphy Maura
Dinehart Kirk
Hurter Patricia
Connelly Patrick
Cui Yong
Riccardo N Panicucci
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ZA200700030B publication Critical patent/ZA200700030B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
ZA200700030A 2004-06-08 2005-06-08 Pharmaceutical compositions ZA200700030B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57804304P 2004-06-08 2004-06-08

Publications (1)

Publication Number Publication Date
ZA200700030B true ZA200700030B (en) 2009-06-24

Family

ID=35510250

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200700030A ZA200700030B (en) 2004-06-08 2005-06-08 Pharmaceutical compositions
ZA200802676A ZA200802676B (en) 2004-06-08 2008-03-26 Pharmaceutical compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200802676A ZA200802676B (en) 2004-06-08 2008-03-26 Pharmaceutical compositions

Country Status (18)

Country Link
US (2) US20060089385A1 (xx)
EP (1) EP1765283A4 (xx)
JP (2) JP2008501802A (xx)
KR (2) KR101370580B1 (xx)
CN (2) CN102512372A (xx)
AR (1) AR049297A1 (xx)
AU (1) AU2005253957B2 (xx)
BR (1) BRPI0511900A (xx)
CA (1) CA2569310A1 (xx)
IL (2) IL179809A (xx)
MX (1) MXPA06014253A (xx)
NO (1) NO20070130L (xx)
NZ (1) NZ588471A (xx)
RU (1) RU2373923C2 (xx)
SG (1) SG153800A1 (xx)
TW (1) TWI389688B (xx)
WO (1) WO2005123076A2 (xx)
ZA (2) ZA200700030B (xx)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL194025B1 (pl) * 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
AU2006252553B2 (en) 2005-06-02 2012-03-29 Merck Sharp & Dohme Corp. Combination of HCV protease inhibitors with a surfactant
PL1891089T3 (pl) 2005-06-02 2015-05-29 Merck Sharp & Dohme Inhibitory proteazy HCV w połączeniu z pokarmem
CA2617679A1 (en) 2005-08-02 2007-02-08 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
AU2007217355B2 (en) * 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
JP5646814B2 (ja) 2006-03-06 2014-12-24 アッヴィ・インコーポレイテッド Ｈｃｖを治療するためのリトナビルの組成物及び使用方法
MX2008011868A (es) 2006-03-16 2008-12-15 Vertex Pharma Inhibidores deuterados de la proteasa de la hepatitis c.
MX2008011976A (es) * 2006-03-20 2009-04-07 Vertex Pharma Composiciones farmaceuticas.
CN101494979A (zh) * 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 药物组合物
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
WO2007120595A2 (en) * 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
WO2008074035A1 (en) * 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
CA2679028A1 (en) * 2007-02-23 2008-08-28 Avera Pharmaceuticals, Inc. Pharmaceutical formulation
US8575208B2 (en) * 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
ES2379905T3 (es) * 2007-02-27 2012-05-04 Vertex Pharmceuticals Incorporated Co-cristales y composiciones farmacéuticas que los comprenden
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
EP2000139A1 (en) * 2007-06-07 2008-12-10 Novartis AG Stabilized amorphous forms of imatinib mesylate
NZ583699A (en) * 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
AR068756A1 (es) 2007-10-10 2009-12-02 Novartis Ag Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c
PE20091041A1 (es) * 2007-10-19 2009-08-22 Abbott Gmbh & Co Kg Producto de dispersion solida que contiene un compuesto a base de n-aril urea
WO2009061395A2 (en) * 2007-11-05 2009-05-14 Vertex Pharmaceuticals Incorporated Hcv combination therapies
EA201170484A1 (ru) 2008-09-24 2012-03-30 Вертекс Фармасьютикалз Инкорпорейтед Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
ES2552386T3 (es) 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
EP2539320A1 (en) * 2010-02-25 2013-01-02 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg A process for the preparation of substituted prolyl peptides and similar peptidomimetics
TW201208704A (en) 2010-07-14 2012-03-01 Vertex Pharma Palatable pharmaceutical composition
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
MX2013010306A (es) * 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2907505A3 (en) * 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
ITMI20120608A1 (it) * 2012-04-13 2013-10-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali in forma amorfa
WO2013178031A1 (en) * 2012-06-01 2013-12-05 Sunshine Lake Pharma Co., Ltd. New forms of telaprevir and preparation methods thereof
WO2014096343A1 (en) * 2012-12-21 2014-06-26 Sandoz Ag Novel forms of telaprevir
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
US9732076B2 (en) 2013-03-15 2017-08-15 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of HCV inhibitor in the amorphous state
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110193013B (zh) * 2019-07-02 2022-02-08 力品药业(厦门)股份有限公司 一种去乙酰真菌环氧乙酯固体分散体及其制备方法
WO2023225029A1 (en) * 2022-05-16 2023-11-23 Day One Biopharmaceuticals, Inc. Oral liquid suspension of pan-raf kinase inhibitor
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
EP1970052A2 (en) * 1999-02-09 2008-09-17 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US6627760B1 (en) * 2001-06-25 2003-09-30 Astrazeneca Ab Amorphous compound
ES2234451T1 (es) * 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
DK1677827T3 (da) * 2003-10-27 2009-03-30 Vertex Pharma Kombinationer til HCV-behandling
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途

Also Published As

Publication number Publication date
RU2006147247A (ru) 2008-07-20
NZ588471A (en) 2012-02-24
RU2373923C2 (ru) 2009-11-27
EP1765283A4 (en) 2012-11-28
AU2005253957A1 (en) 2005-12-29
TWI389688B (zh) 2013-03-21
US20060089385A1 (en) 2006-04-27
CN1988885A (zh) 2007-06-27
WO2005123076A3 (en) 2006-06-15
IL222003A0 (en) 2012-12-02
WO2005123076A2 (en) 2005-12-29
US20130274180A1 (en) 2013-10-17
IL179809A0 (en) 2007-05-15
AU2005253957B2 (en) 2011-08-25
JP5337262B2 (ja) 2013-11-06
AR049297A1 (es) 2006-07-12
BRPI0511900A (pt) 2008-01-22
CN102512372A (zh) 2012-06-27
CA2569310A1 (en) 2005-12-29
EP1765283A2 (en) 2007-03-28
JP2008501802A (ja) 2008-01-24
IL179809A (en) 2012-10-31
ZA200802676B (en) 2009-12-30
JP2012067138A (ja) 2012-04-05
NO20070130L (no) 2007-01-25
KR20120039763A (ko) 2012-04-25
KR101370580B1 (ko) 2014-03-06
KR20070030270A (ko) 2007-03-15
SG153800A1 (en) 2009-07-29
TW200608975A (en) 2006-03-16
MXPA06014253A (es) 2007-07-13

Similar Documents

Publication Publication Date Title
IL223545A0 (en) Pharmaceutical compositions
IL179809A0 (en) Pharmaceutical compositions
GB0408308D0 (en) Pharmaceutical compositions
IL177480A0 (en) Pharmaceutical composition
PL1837019T3 (pl) Kompozycja farmaceutyczna rozpadająca się w ustach
IL188352A0 (en) Pharmaceutical compositions
ZA200804103B (en) Pharmaceutical compositions
GB0405033D0 (en) Novel pharmaceutical compositions
GB0406378D0 (en) Novel pharmaceutical compositions
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0522045D0 (en) Pharmaceutical compositions
IL192091A0 (en) Pharmaceutical compositions
GB0406380D0 (en) Novel pharmaceutical compositions
HU0401177D0 (en) Pharmaceutical composition
GB2411355B (en) Pharmaceutical composition
ZA200701932B (en) Pharmaceutical composition
GB0425255D0 (en) Pharmaceutical composition
EP1845944A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA200701931B (en) Pharmaceutical composition
EP1747205A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0502792D0 (en) Pharmaceutical compositions
ZA200803566B (en) Pharmaceutical compositions
HUP0401176A2 (en) Pharmaceutical composition having prpkinetic effect
GB0514259D0 (en) Pharmaceutical compositions
GB0400971D0 (en) Pharmaceutical compositions